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conBACKGROUND Transcatheter left atrial appendage (LAA) ligation may represent an alternative to oral anticoagulation
for stroke prevention in atrial ﬁbrillation.
OBJECTIVES This study sought to assess the early safety and efﬁcacy of transcatheter ligation of the LAA for stroke
prevention in atrial ﬁbrillation.
METHODS This was a retrospective, multicenter study of consecutive patients undergoing LAA ligation with the Lariat
device at 8 U.S. sites. The primary endpoint was procedural success, deﬁned as device success (suture deployment
and <5 mm leak by post-procedure transesophageal echocardiography), and no major complication at discharge (death,
myocardial infarction, stroke, Bleeding Academic Research Consortium bleeding type 3 or greater, or cardiac surgery).
Post-discharge management was per operator discretion.
RESULTS A total of 154 patients were enrolled. Median CHADS2 score (congestive heart failure, hypertension, age
$75 years, diabetes mellitus, prior stroke, transient ischemic attack, or thromboembolism [doubled]) was 3 (interquartile
range: 2 to 4). Device success was 94%, and procedural success was 86%. A major complication occurred in 15 patients
(9.7%). There were 14 major bleeds (9.1%), driven by the need for transfusion (4.5%). Signiﬁcant pericardial effusion
occurred in 16 patients (10.4%). Follow-up was available in 134 patients at a median of 112 days (interquartile range:
50 to 270 days): Death, myocardial infarction, or stroke occurred in 4 patients (2.9%). Among 63 patients with acute
closure and transesophageal echocardiography follow-up, there were 3 thrombi (4.8%) and 13 (20%) with residual leak.
CONCLUSIONS In this initial multicenter experience of LAA ligation with the Lariat device, the rate of acute closure was
high, but procedural success was limited by bleeding. A prospective randomized trial is required to adequately deﬁne
clinical efﬁcacy, optimal post-procedure medical therapy, and the effect of operator experience on procedural
safety. (J Am Coll Cardiol 2014;64:565–72) © 2014 by the American College of Cardiology Foundation.m the *Scripps Clinic, La Jolla, California; yOhioHealth Research Foundation, Riverside Methodist Hospital, Columbus, Ohio;
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566A trial ﬁbrillation is a major risk factorfor stroke and systemic embolism(1). The primary source of thrombo-
embolism in atrial ﬁbrillation appears to be
the left atrial appendage (LAA) (2). Oral anti-
coagulation with vitamin K antagonists
(VKAs) reduces thromboembolic risk and is
recommended for stroke prevention in pa-
tients who are not at very low risk according
to standardized risk scores (1). Novel oralanticoagulant agents are noninferior and in some
cases superior to VKA for the prevention of stroke
and systemic embolism in patients with nonvalvular
atrial ﬁbrillation (3–6). However, both VKAs and theSEE PAGE 573novel oral anticoagulant agents increase the risk of
major bleeding, particularly from a gastrointestinal
source, and are not suitable in a large proportion of
patients because of prohibitive bleeding risk or other
clinical reasons (7,8). Therefore, there exists a sub-
stantial clinical need for alternative approaches to
stroke prevention in atrial ﬁbrillation. A randomized
clinical trial demonstrated that the efﬁcacy of trans-
catheter occlusion of the LAA with a nitinol-based
device and subsequent discontinuation of oral anti-
coagulation was noninferior to VKA (9), and terminal
therapy analysis of this trial further supported the
contention that LAA closure is an effective alter-
native to systemic anticoagulation (10). However, a
permanent implant has several potential limitations,
including device embolism, thrombus formation,
erosion, and infection (9,11–13). These issues may
be mitigated by an “implant-free” approach to LAA
obliteration.
The Lariat device (SentreHeart, Redwood City,
California) allows for the percutaneous ligation of the
LAA through the delivery of a surgical suture via a
combined transseptal and subxiphoid approach (14).
This device has received a section 510(k) clearance
from the U.S. Food and Drug Administration for the
approximation of soft tissue and has been applied to
LAA ligation in approximately 2,000 patients in the
United States, according to the device manufacturer.
To date, the safety and efﬁcacy of this approach have
been explored in a few small, single-center studies
that enrolled patients predominantly outside theentiﬁc; and consulting honoraria with Boston Scientiﬁc, Sentre
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his manuscript’s audio summary by JACC Editor-in-Chief Dr. V
so listen to this issue’s audio summary by JACC Editor-in-Chie
received January 24, 2014; accepted March 17, 2014.United States. The objectives of this multicenter
registry were to determine the clinical characteristics
and post-procedure management of patients under-
going Lariat LAA ligation in current practice within
the United States and to determine the safety and
early efﬁcacy of the procedure.
METHODS
PATIENT SELECTION. This was a retrospective,
multicenter study from 8 sites in the United States of
patients with atrial ﬁbrillation undergoing attempted
transcatheter LAA ligation with the Lariat device for
the purpose of stroke prevention. The enrolled pa-
tients constituted the entire Lariat experience at each
site. An attempted LAA ligation was deﬁned as a
procedure in which pericardial access was attempted,
or transseptal puncture was attempted if done be-
fore pericardial access, with the intent to ligate the
LAA with the Lariat. Patients were not included if
they did not undergo a planned transcatheter LAA
ligation because of issues not pertaining to the pro-
cedure (e.g., LAA thrombus on pre-procedure trans-
esophageal echocardiography [TEE], or if a patient
was screened for the procedure but was not a candi-
date on the basis of ﬁndings of cardiac computed to-
mography [CT].) The institutional review board of the
coordinating center approved the protocol (Scripps
Clinic, La Jolla, California), and each participating
hospital research ethics board provided permission to
collect data.
DATA COLLECTION. Baseline demographics, clinical
and procedural characteristics, in-hospital events,
concomitant medications, follow-up duration, and
out-of-hospital events were collected by use of case
report forms. CHADS2 (congestive heart failure, hy-
pertension, age $75 years, diabetes mellitus, prior
stroke, transient ischemic attack, or thromboembo-
lism [doubled]), CHA2DS2VASC (congestive heart
failure, hypertension, age $75 years [doubled], dia-
betes mellitus, prior stroke or transient ischemic
attack or thromboembolism [doubled], vascular dis-
ease, age 65 to 74 years, sex category), and HAS-BLED
(hypertension, abnormal renal/liver function, stroke,
bleeding history or predisposition, labile INR, elderly,
drugs/alcohol concomitantly) scores (15,16) were
independently calculated by the coordinating centerHeart, St. Jude Medical, Medtronic, and Hansen
relevant to the contents of this paper to disclose.
alentin Fuster.
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TABLE 1 Baseline Demographic and Clinical Characteristics
of the Study Population (n ¼ 154)
Age (yrs) 72.1  9.4
Age >75 yrs 70 (45)
Male 96 (62)
Hypertension 125 (81)
Diabetes mellitus 56 (36)
History of heart failure 53 (34)
Peripheral arterial disease 21 (14)
Prior CVA/TIA 58 (38)
Prior hemorrhagic CVA 21 (14)
Prior major bleed or propensity for bleeding 96 (62)
Labile INR measurements 31 (20)
Concomitant chronic NSAID use 22 (14)
Liver disease 9 (6)
Renal disease 14 (9)
Signiﬁcant alcohol consumption 16 (10)
CHADS2 score 3 (2–4)
CHA2DS2VASC score 4 (3–5)
HAS-BLED score 3 (2–4)
CHADS2 score 2.8  1.4
CHA2DS2VASC score 4.1  1.6
HAS-BLED score 3.2  1.2
Values are mean  SD, n (%), or median (interquartile range).
CHADS2 ¼ congestive heart failure, hypertension, age $75 years, diabetes
mellitus, prior stroke or TIA or thromboembolism (doubled); CHA2DS2VASC ¼
congestive heart failure, hypertension, age$75 years [doubled], diabetes mellitus,
prior stroke or TIA or thromboembolism [doubled], vascular disease, age 65 to
74 years, sex category; CVA ¼ cerebrovascular accident; HAS-BLED ¼ hyperten-
sion, abnormal renal/liver function, stroke, bleeding history or predisposition,
labile INR, elderly, drugs/alcohol concomitantly; INR ¼ international normalized
ratio; IQR ¼ interquartile range; NSAID ¼ nonsteroidal anti-inﬂammatory drug;
TIA ¼ transient ischemic attack.
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567from the appropriate data ﬁelds. All events were site-
reported.
STUDY ENDPOINTS AND DEFINITIONS. Device suc-
cess was deﬁned as suture deployment and a re-
sidual shunt <5 mm by post-procedural TEE. The
primary endpoint was procedural success, deﬁned
as device success, and no major complication at
hospital discharge (death, myocardial infarction [MI],
stroke, major bleeding, or emergency surgery). Other
endpoints included signiﬁcant pericardial effusion,
deﬁned as an effusion requiring further interven-
tion, such as pericardiocentesis or vasopressors for
hemodynamic support; major bleeding; and major
adverse cardiovascular events, deﬁned as death, MI,
or stroke. Major bleeding was deﬁned as Bleeding
Academic Research Consortium type 3 or greater (17).
TRANSCATHETER LAA LIGATION. The Lariat proce-
dure has previously been described in detail (14). In
brief, patients underwent a screening contrast CT
scan to conﬁrm that the LAA anatomy was amenable
to Lariat ligation. Pericardial access was performed
with a micropuncture or 17-G epidural needle, and
a 13.5F soft-tipped sheath was introduced into
the pericardial space over a 0.035-inch guidewire.
Transseptal puncture was then performed via the
femoral vein by a standard technique. Unfractionated
heparin was administered to achieve a goal-activated
clotting time of 250 to 300 seconds. A magnet-tipped
0.025-inch guidewire was advanced into the anterior
aspect of the LAA. A magnet-tipped 0.035-inch wire
was advanced into the pericardium through the
pericardial sheath to form a connection with the
magnet-tipped wire in the LAA, over which the Lariat
snare was advanced and closed at the mouth of the
LAA using TEE and ﬂuoroscopic guidance. The pre-
loaded suture was then released from the snare and
tightened with the suture-tensioning device, and the
snare was removed and the suture cut using a suture
cutter. The pericardial sheath was exchanged for a
drain, which was generally left in place for at least 4
to 6 hours, although the duration of drainage was at
the discretion of the operator. Post-procedure medi-
cal therapy (i.e., analgesic, anti-inﬂammatory and
anticoagulation therapy) was prescribed and clinical
and imaging follow-up (generally, 1 to 3 months post-
procedure) were performed according to operator
preference.
STATISTICAL ANALYSIS. Categorical variables are
reported as counts and percentages and continuous
variables as mean  SD or median and interquartile
range (IQR). Analyses were performed with SPSS
(Statistical Package for the Social Sciences, version
12.0, SPSS Inc., Chicago, Illinois).RESULTS
PATIENT POPULATION. A total of 154 patients were
enrolled at 8 sites (Appendix). A median of 19 pa-
tients (range 5 to 35 patients) were enrolled at each
site. The average age was 72.1  9.4 years; 38%
of patients were female, 36% had diabetes mellitus,
and 14% had a prior hemorrhagic stroke. The median
CHADS2 score was 3 (IQR: 2 to 4), the median
CHA2DS2VASC score was 4 (IQR: 3 to 5), and the me-
dian HAS-BLED score was 3 (IQR: 2 to 4) (Table 1).
Before the procedure, 92 patients (60%) were being
treated with an oral anticoagulant, 43 patients (28%)
were on antiplatelet therapy alone, and 19 patients
(12%) were on no anticoagulant or antiplatelet agent.
PROCEDURAL CHARACTERISTICS. The average pro-
cedure duration was 76.6  2.6 min. In 9 cases, the
suture could not be delivered for the following
reasons: pericardial adhesions preventing either
pericardial sheath placement (2 cases) or limiting
advancement of the epicardial wire or snare (3 cases);
inability to advance the Lariat snare over the LAA
due to challenging anatomy (2 cases); and emergency
TABLE 2 Major Bleeding Events During Hospitalization in
the Study Population (n ¼ 154)*
Major bleed 14 (9.1)
Any transfusion with overt bleeding 7 (4.5)
Overt bleed, hemoglobin drop 3 to <5 g/dl 5 (3.2)
Overt bleed, hemoglobin drop $5 g/dl 3 (1.9)
Cardiac tamponade 7 (4.5)
Bleeding requiring surgical control 2 (1.3)
Bleeding requiring vasoactive agents 4 (2.6)
Fatal bleeding 0
Values are n (%). Bleeding Academic Research Consortium type 3A or greater.
*More than 1 bleeding event may have occurred in a single patient.
TABLE 4 Medical Therapy at Discharge After
Transcatheter Left Atrial Appendage Ligation (n ¼ 154)
Aspirin monotherapy 47 (31)
Dual antiplatelet therapy 37 (24)




No antiplatelet or oral anticoagulation 29 (19)
Clopidogrel monotherapy 11 (7)
Aggrenox 1 (0.6)
Values are n (%).
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568surgery after right ventricular perforation (2 cases).
Among the 145 cases inwhich the suturewas delivered,
TEE demonstrated complete LAA closure at the end of
the procedure in 133 (92%) and a residual leak<5mm in
11 cases (7%) and $5 mm in 1 case. Device success
(delivery of suture and residual leak <5 mm) was
therefore achieved in 144 cases (94%).
PROCEDURAL COMPLICATIONS AND IN-HOSPITAL
OUTCOMES. There were a total of 15 patients (10%)
with at least 1 major periprocedural complication
(death, MI, stroke, major bleed, or emergent cardiac
surgery). Major bleeding occurred in 14 patients
(9%), driven by the need for transfusion (Table 2).
Emergency surgery was required in a total of 3 pa-
tients (2%), 2 for right ventricular perforation during
pericardial access with subsequent cardiac tampo-
nade and 1 for repair of LAA perforation. One patient
died in the hospital 19 days post-procedure of respi-
ratory failure, sepsis, and subsequent nosocomial
pneumonia. There were no in-hospital strokes or MIs.
Overall, procedural success was achieved in 132 pa-
tients (86%) (Table 3).
Signiﬁcant pericardial effusion occurred in 16
patients (10%) and pleural effusion in 4 patients
(3%). The cause of pericardial effusion was thought to
be secondary to LAA perforation/laceration in 4 of
these cases (25%), a result of pericardial access inTABLE 3 Reasons for Procedural Failure of Left
Atrial Appendage Ligation With the Lariat Device (N ¼ 22)
Lariat unable to be deployed 9 (48)
Pericardial adhesions 5
LAA anatomy 2
Aborted procedure after RV perforation 2
Residual Leak $ 5 mm 1 (6)
Major complication before discharge 15 (71)
Values are n or n (%). In 2 patients with procedural failure, there was both a major
complication and the lariat was not deployed. In 1 patient, there was both a
residual leak $ 5 mm and a major complication.
LAA ¼ left atrial appendage; RV ¼ right ventricular.4 cases (25%), and from an unclear cause in the
remainder.
MEDICAL MANAGEMENT AT TIME OF DISCHARGE.
Anticoagulant and/or antiplatelet therapy at dis-
charge was heterogeneous (Table 4). The most
frequent treatment at discharge was aspirin mono-
therapy. No antiplatelet or oral anticoagulant agent
was prescribed in 29 patients (19%).
OUT-OF-HOSPITAL OUTCOMES. Follow-up was avai-
lable in 134 patients (87%) at a median period of
112 days (IQR: 50 to 270 days) after discharge. The
composite of out-of-hospital death, MI, or stroke
occurred in 4 patients (2.9%). There were 3 deaths, 1 of
a noncardiovascular cause and 2 of cardiovascular
causes (sudden death at 22 days post-discharge and
infarcted bowel/stroke at 49 days post-discharge).
Stroke occurred in 2 patients (including 1 who also
died), pericardial effusion occurred in 3 patients, and
late pleural effusions were noted in 3 patients.
RESIDUAL LEAK OVER FOLLOW-UP. TEE follow-up
was performed in 63 patients in whom the Lariat
deployment was successful. Immediately post-
procedure, there was complete LAA closure in 58 pa-
tients (92%) and a leak<5mm in the remainder (8%). At
follow-up, there was complete closure in 50 patients
(79%), a leak <5 mm in 9 patients (14%), and a leak
$5 mm in 4 patients (6%).
THROMBUS FORMATION. Left atrial thrombus origi-
nating near the LAA stump occurred in 3 patients
(5%) with TEE follow-up at 46, 82, and 104 days
post-procedure. These patients had been discharged
post-procedure on aspirin and clopidogrel, aspirin
monotherapy, and no antiplatelet or anticoagulant
agent, respectively. One additional thrombus was
incidentally noted by CT 17 days post-procedure in a
patient who had been noncompliant with dabigatran
therapy. All patients were treated successfully with








•  No device left behind
•  One size fits all
•  Anatomic exclusions
•  Requires pericardial access 
•  Peri-procedural complications, 
    including PE, 
    ventricular perforation, 
    pericarditis
•  Possible late central leak
•  Possible late stump thrombus
•  Optimal post-procedural 
    medication unknown, 
    short-term OAC 
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    and efficacy data
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•  No device left behind
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•  Possible late device thrombus
•  Open surgical procedure
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•  Possible persistent leak 
    or residual LAA stump
•  Optimal post-procedural 
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•  Trans-septal access only
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    well-evaluated in RCTs
CENTRAL ILLUSTRATION LAA Closure
Review of pros and cons with varied methods for closure of the left atrial appendage (LAA)
for stroke prevention. LAA ¼ left atrial appendage; OAC ¼ oral anticoagulation; PE ¼
pericardial effusion; RCT ¼ randomized clinical trial.
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In this multicenter U.S. registry of patients undergo-
ing transcatheter LAA ligation with the Lariat device,
treated patients were at signiﬁcant thromboembolic
risk according to standard risk scores and frequently
had a clinical history consistent with intolerance
of anticoagulant agents. Device success was high
(94%), but procedural success was limited by the
occurrence of major bleeding. Surveillance TEE, when
performed, identiﬁed occasional LAA stump thrombus
(3%) and late leakage into the appendage (20%).
Our ﬁndings provide insight into the results of this
procedure in clinical practice and have important im-
plications regarding patient selection, procedural
technique, and post-procedural management (Central
Illustration).
To date, information regarding the acute safety
and efﬁcacy of transcatheter LAA suture ligation has
been limited to small, single-center studies. The
technical results of the procedure were similar in
the current multicenter study compared with these
previous reports. In a single-center experience, the
Lariat procedure was technically successful in 85 of
92 patients in whom it was attempted (92%), similar
to the 94% success in our study and another,
smaller experience (14,18). The most common
reason for an aborted procedure in our study was
unanticipated pericardial adhesions, observed in
approximately 3% of patients, which were not
detected before the procedure by CT or by echo-
cardiographic imaging. This rate of unanticipated
adhesions was also consistent with a previous
report (14).
The rates of procedural complications and
anatomic closure that we observed differ from prior
reports. Major procedural complications occurred in
10% of cases, most of which were major bleeding
events not related to transseptal access and driven
by the occurrence of blood transfusions and serious
pericardial effusions. Compared with the initial
Lariat experience reported by Bartus et al. (14), our
patient population was substantially older (45%
versus 12% were $75 years of age) and had a higher
prevalence of comorbidities such as heart failure
(34% versus 12%) and diabetes (36% versus 10%),
which may have contributed in part to a greater rate
of complications. Pericardial effusion is also the
most common procedural complication associated
with device occlusion of the LAA. Pericardial effu-
sion occurred in 5% of patients randomly assigned to
the Watchman device (Boston Scientiﬁc, Natick,
Massachusetts) in the PROTECT-AF trial (Percuta-
neous Left Atrial Appendage Closure for StrokeProphylaxis in Patients With Atrial Fibrillation) (9),
although the incidence has decreased to 2.2% with
increased operator experience (19). Unique to the
Lariat procedure, pericardial effusions may result
from right ventricular perforation or irritation during
pericardial access, from tearing the thin LAA wall
during advancement of the magnet-tipped wire
within the LAA during manipulation of the Lariat
snare over the LAA, or during suture tightening.
Acute management of a serious pericardial effusion
during the Lariat procedure may be relatively
straightforward, because a large sheath (albeit
without an aspiration port) is initially placed within
the pericardium, which allows for evacuation of
blood if necessary. However, beyond initial sta-
bilization, the clinical management of pericardial
bleeding may require surgical repair. Additionally,
post-procedure pericardial effusions can develop
that may require drainage. Whether the incidence
of serious pericardial effusion can be reduced
with increasing operator experience and technical
Price et al. J A C C V O L . 6 4 , N O . 6 , 2 0 1 4
Consortium for Transcatheter LAA Ligation A U G U S T 1 2 , 2 0 1 4 : 5 6 5 – 7 2
570reﬁnements, as observed in the CAP (Continuing
Access to PROTECT-AF) registry (19), remains to
be determined. Post-discharge outcomes were less
favorable than previously reported, because the
composite of death, MI, or stroke occurred in 4 pa-
tients (2.9%) and a late pericardial effusion occurred
in 3 patients (2.2%). The causes of these are likely
multifactorial but again may reﬂect a higher severity
of underlying comorbidities in our collective patient
population compared with the initial Lariat experi-
ences (14).
Although we observed a very high acute closure
rate, our results demonstrate that late residual leak
can occur after the Lariat procedure. In a prior
single-center observational study of 85 patients with
successful ligation, there was only 1 leak (<2 mm) in
the 65 patients who underwent surveillance TEE
(14). In contradistinction, we observed a late leak in
20% of the 60 patients who had a surveillance TEE,
approximately one-third of which were $5 mm in
diameter. Potential reasons for this greater rate of
late leak may include patient selection or operator
experience, although this is speculative. Peri-device
leaks were frequent after Watchman implantation
but do not appear to be associated with thrombo-
embolic events (20). Incomplete surgical LAA ligation
has been associated with subsequent thrombus for-
mation and clinical events (21). The clinical conse-
quences of residual leaks after the Lariat procedure,
if any, are unknown, but leaks can be treated suc-
cessfully with percutaneous approaches (22,23),
although the safety and efﬁcacy of such leak closure
are unproven.
This study provides insights into the real-world
application of the Lariat technology in the United
States. Patients who underwent percutaneous LAA
ligation were at high risk for thromboembolic
events. Approximately two-thirds of the patients
had a prior major bleeding event or a propensity for
major bleeding, and 14% had a prior intracranial
bleeding event, which placed them at high risk for
recurrent bleeding on oral anticoagulation. This pa-
tient population was not well represented in the
clinical trial that demonstrated the superiority of
apixaban over aspirin in patients who were not
suitable for or unwilling to take warfarin anti-
coagulation (7). Given the incidence of procedural
complications we observed and the lack of robust,
long-term efﬁcacy data, it appears reasonable that if
percutaneous LAA ligation is to be performed, it
should be reserved for individuals at substantial
thromboembolic and bleeding risk who are not can-
didates for prospective U.S. Food and Drug Admin-
istration studies of LAA occlusion. Furthermore,whether a percutaneous approach to surgical ligation
with the Lariat procedure provides any advantage
over minimally invasive surgical ligation (24) de-
serves exploration.
Medical therapy at discharge after the Lariat
procedure was heterogeneous. In addition to our
experience, several cases of LAA thrombus after
the Lariat procedure have been reported (25,26).
Although our study has insufﬁcient power to iden-
tify predictors of post-procedure thrombus forma-
tion, it would appear reasonable to administer at
least a short course of post-procedural oral anti-
coagulation until follow-up imaging is performed,
given our ﬁndings of occasional thrombus formation
in patients treated with no therapy and with anti-
platelet therapy. Prospective studies are required to
deﬁne the optimal medical regimen post-procedure.
According to our multicenter experience, it appears
that post-procedural TEE is not routinely per-
formed in current real-world practice. However,
given our ﬁndings, routine follow-up imaging ap-
pears advisable.
STUDY LIMITATIONS. Our study has several limita-
tions. It is retrospective, and all events were site-
reported. Patient management and clinical and im-
aging follow-up were not uniform; however, one
objective of this study was to describe how percu-
taneous LAA ligation is currently being used within
the United States. Pericardial effusion can be chal-
lenging to deﬁne after the Lariat procedure, but
we limited our deﬁnition to effusions that required
intervention because of hemodynamic compromise
or had other clinical sequelae. Data regarding post-
procedural chest pain, pericardial drainage, and
pericarditis were not routinely collected. It is un-
known what size residual leak is of clinical impor-
tance. Although the deﬁnition of a signiﬁcant leak
used in this study is consistent with that of the
PROTECT-AF trial, in which warfarin was continued
over follow-up if there was peri-device ﬂow $5 mm,
we may have underestimated the incidence of clin-
ically important leaks with the Lariat device. There
was a broad range in the number of patients enrolled
at each site. Increasing operator experience could be
associated with improved outcomes. However, given
the study size, we did not have statistical power to
identify interactions, if any, between outcomes and
site, operator experience, or post-procedure medical
therapy.
CONCLUSIONS
In this ﬁrst multicenter report of clinical outcomes
after transcatheter ligation of the LAA with the Lariat
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The Lariat de-
vice is designed to facilitate percutaneous catheter-based liga-
tion of the left atrial appendage to prevent stroke in patients
with nonvalvular atrial ﬁbrillation using combined transseptal
and transpericardial approaches. The most frequent acute com-
plications of the procedure are hemopericardium and other major
bleeding.
TRANSLATIONAL OUTLOOK: Proper assessment of the
relative safety and efﬁcacy of the Lariat device as an alternative
to long-term anticoagulant therapy in patients with atrial
ﬁbrillation will require carefully designed randomized
trials that address both thromboembolism and bleeding
outcomes.
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571device, device success was high, but procedural suc-
cess was limited by major bleeding, which occurred in
9% of cases. Occasional thrombus and late leak were
observed on imaging follow-up. A large prospective
trial is required to adequately deﬁne safety, clinical
efﬁcacy, and post-procedure management. Until such
data are available, consideration for the procedure
should be limited to patients who are at high risk for
thromboembolic events and bleeding and are not
candidates for currently enrolling protocols of LAA
occlusion.
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APPENDIX Participating Sites and Enrollment:
Scripps Clinic, La Jolla, CA (36); Houston
Methodist Hospital, Houston, TX (35); St
David’s Hospital, Austin, TX (24); Cottage
Hospital, Santa Barbara, CA (19); Banner
Hospital, Phoenix, AZ (19); Riverside Methodist
Hospital, Columbus, OH (9); Prairie Heart
Cardiology, Springﬁeld, IL (7); Northwestern
University, Chicago, II (5).
